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sequenced by Sanger. The results conﬁrmed the
presence of an RNA transcript spanning exon 19 of
MPRIP and exon 12 of RET. Furthermore, FISH was
performed with the RET (10q11.2) break-apart probe,
and conﬁrmed the rearrangement involving the RET
region of chromosome 10.
Conclusions: These results show the ArcherTM Fusion-
PlexTM Lung Thyroid Panel can accurately detect gene
fusions with both known and unknown partner and
driver genes. Further investigation is needed to better
understand the clinical signiﬁcance and prevalence of
the novel MPRIP and RET fusion.
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Inﬂammation often characterizes the pulmonary tumor
microenvironment, as does overexpression of the tran-
scriptional repressors of E-cadherin (e.g., Snail and Slug).
While chronic inﬂammation is now associated with
increased lung cancer incidence, Snail and Slug are still
best known for their induction of epithelial-mesen-
chymal transition (EMT) and their contribution to the
progression of established lung cancer. Our bioinfor-
matics analysis of lung TCGA data suggests that Slug is
among the most impactful of all the transcriptional re-
pressors on patient survival. Therefore, we are now
exploring the scope of malignant phenotypes and
mechanisms induced by Slug expression in a non-small
cell lung cancer (NSCLC) model. We discovered that
NSCLC cells exposed to the prototypical inﬂammatory
mediator IL-1B respond with downregulation of epithe-
lial markers (E-cadherin and cytokeratin 18) and upre-
gulation of mesenchymal markers (N-cadherin and
vimentin), with the repression of E-cadherin by IL-1B
being Slug-dependent. NSCLC cells exposed to IL-1B also
demonstrate altered cellular morphology, diminished
capacity to form clusters in a 3-dimensional (3D)
spheroid model, and increased motility. Using chemical
inhibitors of the JNK, MEK/ERK, p38 MAPK, and NF-lB
pathways, we determined that JNK and MEK/ERK
mediate IL-1B induction of EMT in lung cancer cells.
Furthermore, siRNA-mediated knockdown of the Fra-1
component of the AP-1 transcription factor abolished the
impact of IL-1B on Slug and E-cadherin in this model,demonstrating a mechanistic link between inﬂammation
and Slug-dependent progression of established lung
cancer. Because we have identiﬁed a critical role for
Snail in lung cancer initiation, we next investigated the
contribution of Slug to early lung cancer development.
Using human bronchial epithelial cells (HBECs) engi-
neered to express Slug to model pulmonary pre-
malignancy, we observed a diverse array of potentially
malignant phenotypes, including EMT, increased pro-
duction of the pro-angiogenic chemokine CXCL8,
enhanced invasion in a 3D air-liquid interface model, and
anchorage-independent growth in vitro. Furthermore,
we determined that the Slug-driven transformation
observed in vitro was not contingent upon an altered
proliferation rate, but was more likely related to Slug-
driven disruption of stem cell signaling programs. Taken
together, our data suggest that Slug may be important
in the setting of lung carcinogenesis and that its impact
on carcinogenesis extends beyond its repression of
E-cadherin. Our data also suggest that Slug may play an
important role in the initiation and progression of early
stage NSCLC.
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Playing a central role in regulating DNA synthesis and
repair, proliferating cell nuclear antigen (PCNA) is
indispensable to cancer cell growth and survival. It,
therefore, represents a potential molecular target to
develop broad-spectrum anti-cancer agents. We discov-
ered a cancer-associated isoform of PCNA (caPCNA),
which is ubiquitously and highly expressed in a broad
range of cancer cells and tumor tissues. In contrast, this
PCNA isoform is not signiﬁcantly expressed in non-
malignant cells. The secondarily modiﬁed region dis-
tinguishing caPCNA from normal PCNA expressed in
non-malignant cells lies between L126 and Y133 within
the interconnector domain of PCNA known to be a major
binding site for many of PCNA’s interacting proteins. A
cell permeable peptide containing the L126-Y133
sequence blocks PCNA interaction, interferes with
DNA replication and homologous combination mediated
DNA repair, and induces apoptosis in cancer cells. In
contrast, this peptide causes no signiﬁcant toxicity to
